

Text Searchable Document

Shaughnessy No: 080803

Date Out of EAB: JUN | 0 1988

TO: Robert J. Taylor/Cynthia Giles Product Manager #25 Registration Division (TS-767C)

FROM: Emil Regelman Environmental Chemistry Review Section #3 Exposure Assessment Branch Hazard Evaluation Division (TS-769C)

THRU: Paul F. Schuda, Chief

Exposure Assessment Branch/HED (TS-769C)

Attached, please find the FAB review of:

Reg./File #: 100-529

Chemical Name: ATRAZINE

Type product: <u>Herbicide</u>

Product Name: <u>AAIRAEX^R NINE-O^R</u>

Company Name: Ciba-Geigy

US EPA ARCHIVE DOCUMEN

Purpose: <u>Review of study submitted in response to Registration Standard</u>

Date Received: 6/8/88 Date Completed: <u>6/9/88</u> Monitoring study requested:_____ Total Reviewing Time: 0.3 day Monitoring study volunteered:____

Action Code: 660

EAB #(s): 80811


Deferrals to: _____ Ecological Effects Branch _____ Residue Chemistry Branch _____ Toxicology Branch



1. CHEMICAL:

Chemical name: 2-chloro-4-ethylamino-6-isopropylamino-<u>s</u>-triazine Chemical Abstracts #: 1912-24-9 Common name: AIRAZINE

Structure:



Physical state: powder Color: white Odor: odorless Melting point: 175-177^oC Boiling point: not applicable Vapor pressure: 3.0x10⁻⁷ mmHg at 20^oC Density: 1.19 gcm⁻³ at 20^oC Solubility at 20^oC:

Water	
Chloroform	5.2%
Diethyl ether	1.3%
Ethyl acetate	
n-pentane	

2. TEST MATERIAL: N/A.

n

3. <u>STUDY/ACTION TYPE</u>: Review of data submitted in response to the ATRAZINE Registration Standard.

4. STUDY IDENTIFICATION:

- Rustum, A.M. 1988. <u>Aerobic, aerobic/anaerobic, and sterile soil</u> <u>metabolism of 14C-ATRAZINE.</u> Conducted by Hazleton Laboratories America, Inc., Madison, WI. Study completed on April 25, 1988. Laboratory Study No. HLA 6015-185. Submitted by Ciba-Geigy Corp., Greensboro, NC. EPA MRID No. 40629303.

-1-

5. <u>REVIEWED BY</u>:

Silvia C. Termes Chemist, Review Section #3 OPP/HED/EAB

Signature

Date

6. APPROVED BY:

Emil Regelman Supervisory Chemist Review Section #3 OPP/HED/EAB

Signature:_(7°le	29	e)	
Date:	JUN	10	1988	· · · · · · · · · · · · · · · · · · ·

7. CONCLUSIONS:

The submitted environmental fate study is being retained at FAB and will be reviewed as part of the FAB Science Chapter for ATRAZINE, which is scheduled for completion (as a FRSIR) on 10/18/88.

8. <u>RECOMMENDATIONS</u>:

No recommendations.

CIBA-GEIGY

Agricultural Division

CIBA-GEIGY Corporation P.O. Box 18300 Greensboro, North Carolina 27419 Telephone 919 292 7100

May 13, 1988

Mr. Robert J. Taylor Product Manager (25) Registration Division (TS-767C) Office of Pesticide Programs U.S. Environmental Protection Agency 1921 Jefferson Davis Highway Crystal Mall 2 - Room 245 Arlington, VA 22202

Dear Mr. Taylor:

SUBJECT: ADDITIONAL DATA FOR ATRAZINE REREGISTRATION ATRAZINE TECHNICAL, EPA REG. NO. 100-529

Enclosed please find three copies each of four (4) data volumes which are being provided as a follow-up to our November 17, 1987 submission of data under the subject action. Included in this submission are the following:

1. <u>Aerobic/anerobic soil metabolism</u> - Originally due on November 17, 1987, an extension was granted for this study until this time in a September 10, 1987 letter from the Agency. In the November 1987 submission, a status of this study was provided.

2. <u>Historical control data for mouse oncogenicity study</u> - In the Agency letter of March 22, 1988, specific information was requested relating to historical control data for the facility where this study was conducted. The enclosed information represents all the available information which meets the criteria spelled out in the Agency letter. This information is intended to supplement the mouse study.

3. <u>Re-evaluation of pathology data for rat combined chronic</u> <u>feeding/oncogenicity study</u> - This supplement contains a re-examination of the original slides from the pathology ceport from this study, conducted at American Biogenics Corporation. The purpose of the re-evaluation was to determine if there was any progression of tumors from benign to malignant in the rat study. This study was submitted to the Agency May 5, 1986 and has subsequently been reviewed and accepted by the Agency. There was a finding of mammary tumors in the study, reported by CIBA-GEIGY, and confirmed by the Agency. It is felt that the enclosed supplement is useful in drawing conclusions about tumor progression and the accuracy of the original tumor

Page 2

identification.

If there are any questions concerning matters contained within this submission, please do not hesitate to contact us.

artan Care

Sincerely, HOMAL , Farall Thomas J. Parshley Regulatory Specialist

Enclosures

÷.